Outcomes from a simulated EU-UK negotiation by Bruegel and Wellcome.
This report is about the lessons from a simulated negotiation of a post-Brexit UK-EU science agreement.
Effective regulatory oversight is needed to make sure emerging science and technologies reach their full potential quickly and safely, and with the public's trust. Our report sets out how the UK can become a world leader in this area.
[Summary] Effective regulatory oversight is needed to make sure emerging science and technologies reach their full potential quickly and safely, and with the public's trust. Our report sets out how the UK can become a world leader in this area.
[Summary] Four realistic and achievable options for regulatory cooperation in UK-EU clinical trials, including costs and opportunities.
We look at how science should be included in the framework for a future EU-UK relationship.
We discuss ways to improve collaboration between the European Commission and private foundations.
With 11 other organisations, we sign a joint statement on ways to improve collaboration between the European Commission and private foundations.
[Summary] Wellcome’s recommendations on what should be included in a new EU-UK research partnership and how it could be delivered. It is based on the views of European and UK experts.
A synthesis of the existing evidence on the EU-UK relationship on research and innovation, produced by the Royal Society.
[Summary] Facts and figures on UK primary science education across the UK – from how science is taught, to what pupils think of it.
Report of a joint Academy of Medical Sciences, Cancer Research UK and Wellcome workshop on the regulation and governance of health research in the UK.
Joint report on the value of UK medical research to EU science and health.
This commissioned review looks at the data infrastructure provision available to Wellcome-funded researchers and suggests areas where improvements could be helpful.
A commissioned review looking at how to make sure data sharing benefits research globally.
We propose concrete interventions to combat the real and growing threat of antimicrobial resistance.
We commissioned Ipsos MORI to undertake research into public attitudes towards commercial organisations accessing health, medical and genetic data.
A national survey, on behalf of a consortium of UK public research funders, into the factors that affect public engagement by researchers across the UK.
We examined the potential use of diagnostic tools to guide antibiotic use in a range of common clinical scenarios.
We commissioned independent consultants Technopolis to study the types of clinical research that use data from trials.